International: +1-347-960-6455
Strategic Advancements in Drug Development are Beholding the Growth of Proteasome Inhibitors Pipeline

According to a new research report Proteasome Inhibitors – Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments” published by Pharma Proff, proteasome inhibitors currently exhibit a proliferating pipeline with 20+ therapeutic candidates.

Proteasome Inhibitors Pipeline Insights

Proteasomes are small, barrel-formed structures found in cells having a function of degrading the misfolded and non-useful proteins inside the cells. Proteasome inhibitors focus on proteasomes in the disease cells and hinder their action by binding to them. Once, proteasome action is lost, the proteins begin to assemble inside the malignant cells and later burst due to overaccumulation, causing cell death. The proteasome inhibitors are being considered for the treatment of various diseases, including myeloma and immune system related disorders.

Velcade and Ninlaro of Takeda Pharmaceutical Company Limited are the approved proteasome inhibitors by the U.S. Food and Drug Administration (USFDA) for the treatment of multiple myeloma. Also, Velcade is approved inhibitor for the treatment of mantle cell lymphoma.

Insights into Pipeline Segments

According to the research findings, majority of the pipeline drug candidates are being developed to be administered by intravenous route. It has been observed that the intravenous route of medication is convenient and provides improved patient’s compliance. Administration of proteasome inhibitors through intravenous route has also shown promising results in clinical studies.

Positive Clinical Results Play a Pivotal Role in Proteasome Inhibitors Development

Companies that are involved in developing proteasome inhibitors have shown positive clinical results in the various phases of drug development. For instance, in May 2016, Conatus Pharmaceuticals Inc. announced positive topline data of phase II trial of Emricasan for the treatment of liver cirrhosis. The data demonstrated that Emricasan had a favorable safety profile and was well-tolerated.

Browse Detailed Report at:

Strategic Advancements Play a Pivotal Role in Proteasome Inhibitors Development

It has been observed that many pharmaceutical companies are entering into merger & acquisitions for the development of proteasome inhibitors and their geographical expansion. For instance, in April 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals Inc. for $8.8 billion. Later in November 2009, Millennium Pharmaceuticals Inc., which became the wholly-owned subsidiary of Takeda Pharmaceutical Company Limited initiated a Phase I clinical trial of MLN9708, a second-generation proteasome inhibitor.

Takeda Pharmaceutical Company Limited, Amgen Inc., Conatus Pharmaceuticals Inc., Hibiskus Biopharma Inc., and Celgene Corporation are some of the companies involved in the development of proteasome inhibitors.

Proteasome Inhibitors Pipeline Analysis

  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company

The report comprises detailed pipeline analysis of proteasome inhibitors under development. Comprehensive insights on the pipeline products have been provided, with special focus on strategic developments of key players, information on drug licensing, designations, financing, and grants, technological advancements, patents, and upcoming conferences. In addition, the report highlights the winning strategies of companies involved in the development of proteasome inhibitors. Detailed regulatory approval procedures in the U.S., Europe, and Japan are also provided in this report. Furthermore, the report contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanisms of action, and drug origin with respect to proteasome inhibitors.